TWSE:1783

Stock Analysis Report

NOT FOR DISTRIBUTION
Header cover image

Market Cap

NT$2.4b

Last Updated

2021/06/17 14:02 UTC

Data Sources

Company Financials

Executive Summary

Maxigen Biotech Inc. engages in the development, manufacture, and marketing of biomedical and skincare products in Taiwan and internationally. More Details


Snowflake Analysis

Flawless balance sheet with acceptable track record.

Share Price & News

How has Maxigen Biotech's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: 1783 is not significantly more volatile than the rest of TW stocks over the past 3 months, typically moving +/- 8% a week.

Volatility Over Time: 1783's weekly volatility (8%) has been stable over the past year.


Market Performance


7 Day Return

-3.0%

1783

-0.2%

TW Personal Products

1.3%

TW Market


1 Year Return

-1.9%

1783

-8.3%

TW Personal Products

48.5%

TW Market

Return vs Industry: 1783 exceeded the TW Personal Products industry which returned -5.5% over the past year.

Return vs Market: 1783 underperformed the TW Market which returned 48.1% over the past year.


Shareholder returns

1783IndustryMarket
7 Day-3.0%-0.2%1.3%
30 Day8.0%3.7%8.1%
90 Day19.1%-5.0%8.0%
1 Year1.0%-1.9%-5.1%-8.3%53.3%48.5%
3 Year4.4%-1.6%-5.8%-13.4%75.9%55.7%
5 Year73.1%63.2%31.7%14.3%140.8%97.9%

Long-Term Price Volatility Vs. Market

How volatile is Maxigen Biotech's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Maxigen Biotech undervalued compared to its fair value and its price relative to the market?

32.13x

Price to Earnings (PE) ratio


Share Price vs. Fair Value

Below Fair Value: 1783 (NT$34.35) is trading above our estimate of fair value (NT$14.54)

Significantly Below Fair Value: 1783 is trading above our estimate of fair value.


Price To Earnings Ratio

PE vs Industry: 1783 is poor value based on its PE Ratio (32.1x) compared to the TW Personal Products industry average (15.5x).

PE vs Market: 1783 is poor value based on its PE Ratio (32.1x) compared to the TW market (17.5x).


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate 1783's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: 1783 is overvalued based on its PB Ratio (2.7x) compared to the TW Personal Products industry average (2.2x).


Future Growth

How is Maxigen Biotech forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?

18.8%

Forecasted Household industry annual growth in earnings


In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Maxigen Biotech has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Past Performance

How has Maxigen Biotech performed over the past 5 years?

54.4%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: 1783 has a large one-off gain of NT$22.5M impacting its March 31 2021 financial results.

Growing Profit Margin: 1783's current net profit margins (16.1%) are higher than last year (13.7%).


Past Earnings Growth Analysis

Earnings Trend: 1783 has become profitable over the past 5 years, growing earnings by 54.4% per year.

Accelerating Growth: 1783's earnings growth over the past year (17.7%) is below its 5-year average (54.4% per year).

Earnings vs Industry: 1783 earnings growth over the past year (17.7%) exceeded the Personal Products industry 4.7%.


Return on Equity

High ROE: 1783's Return on Equity (8.5%) is considered low.


Financial Health

How is Maxigen Biotech's financial position?


Financial Position Analysis

Short Term Liabilities: 1783's short term assets (NT$459.9M) exceed its short term liabilities (NT$86.4M).

Long Term Liabilities: 1783's short term assets (NT$459.9M) exceed its long term liabilities (NT$9.1M).


Debt to Equity History and Analysis

Debt Level: 1783 is debt free.

Reducing Debt: 1783 has no debt compared to 5 years ago when its debt to equity ratio was 35%.

Debt Coverage: 1783 has no debt, therefore it does not need to be covered by operating cash flow.

Interest Coverage: 1783 has no debt, therefore coverage of interest payments is not a concern.


Balance Sheet


Dividend

What is Maxigen Biotech current dividend yield, its reliability and sustainability?

2.36%

Current Dividend Yield


Dividend Yield vs Market

Notable Dividend: 1783's dividend (2.36%) is higher than the bottom 25% of dividend payers in the TW market (2.04%).

High Dividend: 1783's dividend (2.36%) is low compared to the top 25% of dividend payers in the TW market (5.01%).


Stability and Growth of Payments

Stable Dividend: Whilst dividend payments have been stable, 1783 has been paying a dividend for less than 10 years.

Growing Dividend: 1783's dividend payments have increased, but the company has only paid a dividend for 3 years.


Current Payout to Shareholders

Dividend Coverage: At its current payout ratio (75.8%), 1783's payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: Insufficient data to determine if a dividend will be paid in 3 years and that it will be covered by earnings.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

1.4yrs

Average board tenure


CEO

Sung-Ching Chen

no data

Tenure

Dr. Sung-Ching Chen, Ph.D, serves as President at Maxigen Biotech Inc. and serves as its Director since 2020. He serves as Vice President of Biomedical at Maxigen Biotech Inc. Dr. Chen joined the BioMedica...


Board Members

Experienced Board: 1783's board of directors are not considered experienced ( 1.4 years average tenure), which suggests a new board.


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Company Information

Maxigen Biotech Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Maxigen Biotech Inc.
  • Ticker: 1783
  • Exchange: TWSE
  • Founded: 1998
  • Industry: Personal Products
  • Sector: Household
  • Market Cap: NT$2.386b
  • Shares outstanding: 69.47m
  • Website: https://www.mbi.com.tw

Location

  • Maxigen Biotech Inc.
  • No. 88, Keji 1st Road
  • Guishan District
  • Taoyuan City
  • 333
  • Taiwan

Listings


Biography

Maxigen Biotech Inc. engages in the development, manufacture, and marketing of biomedical and skincare products in Taiwan and internationally. The company offers Formagraft, a bone graft substitute; Formas...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2021/06/17 14:02
End of Day Share Price2021/06/17 00:00
Earnings2021/03/31
Annual Earnings2020/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.